Published in Anticancer Agents Med Chem on January 01, 2007
1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets. Curr Med Chem (2009) 1.19
Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells. Cell Commun Signal (2008) 1.05
Peptide targeting of platinum anti-cancer drugs. Bioconjug Chem (2009) 0.94
Bis[3,5-bis(benzylidene)-4-oxo-1-piperidinyl]amides: a novel class of potent cytotoxins. ChemMedChem (2011) 0.88
Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate. Bioorg Med Chem Lett (2011) 0.87
Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: synthesis and comparison with carboplatin in normal and Pt-resistant cell lines. Dalton Trans (2009) 0.87
Texaphyrins: tumor localizing redox active expanded porphyrins. Anticancer Agents Med Chem (2011) 0.84
A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. Medchemcomm (2012) 0.83
Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity. Chem Biodivers (2012) 0.80
Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. J Biol Inorg Chem (2013) 0.79
Metalloprobes: synthesis, characterization, and potency of a novel gallium(III) complex in human epidermal carcinoma cells. J Inorg Biochem (2007) 0.77
Advances in drug delivery system for platinum agents based combination therapy. Cancer Biol Med (2015) 0.75
1,3-diaryl-2-propenones and 2-benzylidene-1,3-indandiones: a quest for compounds displaying greater toxicity to neoplasms than normal cells. Arch Pharm (Weinheim) (2010) 0.75
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem (2005) 2.24
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem (2006) 1.77
Antitumour metal compounds: more than theme and variations. Dalton Trans (2007) 1.64
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev (2006) 1.55
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J Med Chem (2009) 1.51
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem (2009) 1.32
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers (2008) 1.27
Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes. Inorg Chem (2003) 1.25
Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J Med Chem (2007) 1.19
Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem (2005) 1.18
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans (2006) 1.10
Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem (2010) 1.09
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J Med Chem (2007) 1.09
Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J Med Chem (2007) 1.08
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. J Inorg Biochem (2010) 1.04
Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands. Inorg Chem (2011) 1.04
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. J Biol Inorg Chem (2010) 1.03
The first metal-based paullone derivative with high antiproliferative activity in vitro. Inorg Chem (2006) 1.02
Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol (2005) 1.01
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett (2005) 1.01
Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. J Inorg Biochem (2007) 1.01
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom (2009) 1.01
Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans (2009) 1.00
Gallium in cancer treatment. Curr Top Med Chem (2004) 0.98
Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone. J Inorg Biochem (2002) 0.97
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J Med Chem (2005) 0.97
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem (2010) 0.96
Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. Eur J Med Chem (2011) 0.96
Carbohydrate-metal complexes and their potential as anticancer agents. Curr Med Chem (2008) 0.95
Relevance of peat-draining rivers for the riverine input of dissolved iron into the ocean. Sci Total Environ (2010) 0.93
Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties. Inorg Chem (2007) 0.93
Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor. Nucl Med Biol (2008) 0.93
The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro. Inorg Chem (2007) 0.93
Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. J Inorg Biochem (2008) 0.92
Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. J Biol Inorg Chem (2012) 0.92
Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs. Chem Commun (Camb) (2012) 0.92
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anticancer Drugs (2009) 0.91
X-ray absorption spectroscopy of an investigational anticancer gallium(III) drug: interaction with serum proteins, elemental distribution pattern, and coordination of the compound in tissue. J Med Chem (2012) 0.91
Synthesis, structure, spectroscopic properties, and antiproliferative activity in vitro of novel osmium(III) complexes with azole heterocycles. Inorg Chem (2008) 0.90
Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter? Inorg Chem (2010) 0.90
Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin. Dalton Trans (2009) 0.90
Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine. Nanomedicine (2011) 0.90
Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. Dalton Trans (2012) 0.89
CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J Inorg Biochem (2007) 0.89
Novel endothall-containing platinum(IV) complexes: synthesis, characterization, and cytotoxic activity. Chem Biodivers (2008) 0.89
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents. Inorg Chem (2011) 0.89
Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Organometallics (2010) 0.89
X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). J Med Chem (2013) 0.88
A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? ChemMedChem (2007) 0.88
Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: separation of diastereomers and estimation of octanol-water partition coefficients. Electrophoresis (2005) 0.88
Phosphite-derivatized ruthenium-carbohydrate complexes in the catalytic hydration of nitriles. short communication. Chem Biodivers (2008) 0.88
Microfluidic preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2--comparison with conventional radiosyntheses. Nucl Med Biol (2010) 0.87
Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis (2004) 0.87
Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma. Electrophoresis (2008) 0.87
Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands. J Inorg Biochem (2012) 0.87
Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics (2013) 0.86
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. J Inorg Biochem (2012) 0.86
Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences. Dalton Trans (2010) 0.86
Mono-carboxylated diaminedichloridoplatinum(IV) complexes--selective synthesis, characterization, and cytotoxicity. Dalton Trans (2011) 0.86
Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans (2007) 0.86
High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides. Inorg Chem (2008) 0.86
Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study. Dalton Trans (2011) 0.86
An electrochemical study of antineoplastic gallium, iron and ruthenium complexes with redox noninnocent alpha-N-heterocyclic chalcogensemicarbazones. Inorg Chem (2008) 0.86
Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and indolo[3,2-d]benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells. Inorg Chem (2011) 0.85
The hydration of chloroacetonitriles catalyzed by mono- and dinuclear Ru(II)- and Os(II)-arene complexes. Chem Biodivers (2008) 0.85
Synthesis and structure-activity relationships of mono- and dialkyl-substituted oxaliplatin derivatives. Eur J Med Chem (2005) 0.85
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer (2013) 0.85
Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds. J Inorg Biochem (2007) 0.85
Extravasation of Pt-based chemotherapeutics - bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). Metallomics (2015) 0.85
[Os(IV)Cl(5)(Hazole)](-) complexes: synthesis, structure, spectroscopic properties, and antiproliferative activity. Inorg Chem (2009) 0.85
Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication. Chem Biodivers (2008) 0.85
Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. J Biol Inorg Chem (2012) 0.84
Novel cis- and trans-configured bis(oxime)platinum(II) complexes: synthesis, characterization, and cytotoxic activity. Inorg Chem (2010) 0.84
Anticancer activity of methyl-substituted oxaliplatin analogs. Mol Pharmacol (2012) 0.84
Natural organic matter and iron export from the Tanner Moor, Austria. Limnologica (2013) 0.84
Strategies for the covalent conjugation of a bifunctional chelating agent to albumin: synthesis and characterization of potential MRI contrast agents. J Inorg Biochem (2010) 0.84
A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines. J Med Chem (2012) 0.84
Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action. Inorg Chem (2005) 0.84
Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N,N-bis(phosphonomethyl)glycine ligand. J Med Chem (2003) 0.83
CE in anticancer metallodrug research--an update. Electrophoresis (2007) 0.83
Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. Electrophoresis (2006) 0.83
Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-. Inorg Chem (2008) 0.83
Gallium and other main group metal compounds as antitumor agents. Met Ions Biol Syst (2004) 0.83
The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes. Electrophoresis (2010) 0.83
Osmium(IV) complexes with 1H- and 2H-indazoles: tautomer identity versus spectroscopic properties and antiproliferative activity. J Inorg Biochem (2012) 0.83
Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges. Electrophoresis (2003) 0.83
Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates. Dalton Trans (2012) 0.82
Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)]. J Inorg Biochem (2008) 0.82
The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Res (2009) 0.82
Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes. J Med Chem (2012) 0.82
Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. J Chromatogr A (2007) 0.82
Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity. J Med Chem (2012) 0.82
Structure-activity relationships of highly cytotoxic copper(II) complexes with modified indolo[3,2-c]quinoline ligands. Inorg Chem (2010) 0.82
Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. J Biol Inorg Chem (2010) 0.82
Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands. Mol Pharmacol (2006) 0.82